Search PubMed⌕ Search

PubMed · 12848592

NXY 059: CPI 22, NXY 059G.

Abstract

NXY 059 [CPI 22, NXY 059G], a nitrone with free radical trapping properties, has potential in the treatment of ischaemic stroke.This profile has been selected from R&D Insight, a pharmaceutical intelligence database produced by Adis International Ltd. NXY 059 is based on Centaur Pharmaceuticals' proprietary Nitrone-Related Therapeutics (NRT) technology. A generic form of NXY 059, NXY 059G, has been synthesised. On 12 December 2002, Centaur Pharmaceuticals was acquired by, and integrated into, Renovis. AstraZeneca has exclusive worldwide rights to NXY 059, under a licence from Centaur Pharmaceuticals; the licensing agreement is continuing with Renovis. Renovis will receive a significant milestone payment and retains a co-promotion option for NXY 059 in the US. In addition, Renovis is entitled to royalties on profits from worldwide sales of the drug once commercialised. Centaur received a cash payment of $US1.25 million, and up to 30% of Renovis stock in exchange for these assets. In May 2003, AstraZeneca announced the initiation of two major phase III pivotal clinical trials to determine the effect of NXY 059 on disability and neurological recovery in acute ischemic stroke patients. The trials, known as the SAINT (Stroke-Acute-Ischaemic-NXY-Treatment) trials, will compare the efficacy and safety of a 72-hour intravenous infusion of NXY 059 given within 6 hours of the onset of symptoms vs placebo. The studies will enrol >3000 patients. The SAINT I trial will involve 200 centres across 24 countries in Europe, Asia, Australia and South Africa. The SAINT II trial will involve patients from approximately 150 sites in the US, Canada and South America. AstraZeneca is evaluating NXY 059 in a phase I clinical study in the US. Phase III trials of NXY 059 have begun in the UK and Sweden for the treatment of stroke. In November 2000, Centaur Pharmaceuticals announced that the Japanese regulatory authorities approved AstraZeneca's regulatory filings for phase I clinical studies of NXY 059 in Japan. The purpose of these studies is to investigate the safety and tolerability of 8h and 24h IV infusions of NXY 059 in 56 healthy Japanese male subjects. A secondary objective will be to evaluate the pharmacokinetics of NXY 059 in these volunteers.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Adis International Ltd. 2003. NXY 059: CPI 22, NXY 059G.. https://doi.org/10.2165/00126839-200304040-00008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Silica-supported sodium sulfonate with ionic liquid: a neutral catalyst system for Michael reactions of indoles in water.

A neutral catalytic system for Michael reactions of indoles has been developed by combining silica-supported benzenesulfonic acid sodium salt with hydrophobic ionic liquid in water. An efficient hydrophobic environment could be created on the surface of the silica-sodium material under the conditions. Various indole derivatives and alpha,beta-unsaturated carbonyl compounds including some acid-labile substrates were successfully applied to this system with water as the sole solvent to afford the desired Michael adducts in high yields. [structure: see text].

Benzenesulfonates↗

Surfactant-type Brønsted acid catalyzed dehydrative nucleophilic substitutions of alcohols in water.

A protocol for the dehydrative nucleophilic substitution of benzyl alcohols with a variety of carbon- and heteroatom-centered nucleophiles using dodecylbenzenesulfonic acid (DBSA) as a surfactant-type Brønsted acid catalyst in water has been developed. The reaction system can be applied to the stereoselective C-glycosylation of 1-hydroxy sugars in water. [reaction: see text].

Benzenesulfonates↗

Observation of an unusually facile fragmentation pathway of gas-phase peptide ions: a study on the gas-phase fragmentation mechanism and energetics of tryptic peptides modified with 4-sulfophenyl isothiocyanate (SPITC) and 4-chlorosulfophenyl isocyanate (SPC) and their 18-crown-6 complexes.

Various peptide modifications have been explored recently to facilitate the acquisition of sequence information. N-terminal sulfonation is an interesting modification because it allows unambiguous de novo sequencing of peptides, especially in conjunction with MALDI-PSD-TOF analysis; such modified peptide ions undergo fragmentation at energies lower than those required conventionally for unmodified peptide ions. In this study, we systematically investigated the fragmentation mechanisms of N-terminal sulfonated peptide ions prepared using two different N-terminal sulfonation reagents: 4-sulfophenyl isothiocyanate (SPITC) and 4-chlorosulfophenyl isocyanate (SPC). Collision-induced dissociation (CID) of the SPC-modified peptide ions produced a set of y-series ions that were more evenly distributed relative to those observed for the SPITC-modified peptides; y(n-1) ion peaks were consistently and significantly larger than the signals of the other y-ions. We experimentally investigated the differences between the dissociation energies of the SPITC- and SPC-modified peptide ions by comparing the MS/MS spectra of the complexes formed between the crown ether 18-crown-6 (CE) and the modified peptides. Upon CID, the complexes formed between 18-crown-6 ether and the protonated amino groups of C-terminal lysine residues underwent either peptide backbone fragmentation or complex dissociation. Although the crown ether complexes of the unmodified ([M + CE + 2H]2+) and SPC-modified ([M* + CE + 2H]2+) peptides underwent predominantly noncovalent complex dissociation upon CID, the low-energy dissociations of the crown ether complexes of the SPITC-modified peptides ([M' + CE + 2H]2+) unexpectedly resulted in peptide backbone fragmentations, along with a degree of complex dissociation. We performed quantum mechanical calculations to address the energetics of fragmentations observed for the modified peptides.

Benzenesulfonates↗